• Something wrong with this record ?

Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder

S. Vallo, C. Gilfrich, M. Burger, B. Volkmer, K. Boehm, M. Rink, FK. Chun, F. Roghmann, V. Novotny, J. Mani, A. Brisuda, R. Mayr, R. Stredele, J. Noldus, M. Schnabel, M. May, HM. Fritsche, A. Pycha, T. Martini, M. Wirth, J. Roigas, PJ. Bastian,...

. 2016 ; 34 (10) : 432.e1-8. [pub] 20160606

Language English Country United States

Document type Comparative Study, Journal Article

Persistent link   https://www.medvik.cz/link/bmc18011166

PURPOSE: To evaluate the prognostic relevance of different prostatic invasion patterns in pT4a urothelial carcinoma of the bladder (UCB) after radical cystectomy. MATERIALS AND METHODS: Our study comprised a total of 358 men with pT4a UCB. Patients were divided in 2 groups-group A with stromal infiltration of the prostate via the prostatic urethra with additional muscle-invasive UCB (n = 121, 33.8%) and group B with continuous infiltration of the prostate through the entire bladder wall (n = 237, 66.2%). The effect of age, tumor grade, carcinoma in situ, lymphovascular invasion, soft tissue surgical margin, lymph node metastases, administration of adjuvant chemotherapy, and prostatic invasion patterns on cancer-specific mortality (CSM) was evaluated using competing-risk regression analysis. Decision curve analysis was used to evaluate the net benefit of including the variable invasion pattern within our model. RESULTS: The estimated 5-year CSM-rates for group A and B were 50.1% and 66.0%, respectively. In multivariable competing-risk analysis, lymph node metastases (hazard ratio [HR] = 1.73, P<0.001), lymphovascular invasion (HR = 1.62, P = 0.0023), soft tissue surgical margin (HR = 1.49, P = 0.026), absence of adjuvant chemotherapy (HR = 2.11, P<0.001), and tumor infiltration of the prostate by continuous infiltration of the entire bladder wall (HR = 1.37, P = 0.044) were significantly associated with a higher risk for CSM. Decision curve analysis showed a net benefit of our model including the variable invasion pattern. CONCLUSIONS: Continuous infiltration of the prostate through the entire bladder wall showed an adverse effect on CSM. Besides including these patients into clinical trials for an adjuvant therapy, we recommend including prostatic invasion patterns in predictive models in pT4a UCB in men.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18011166
003      
CZ-PrNML
005      
20220720101712.0
007      
ta
008      
180404s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.urolonc.2016.05.008 $2 doi
035    __
$a (PubMed)27283218
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Vallo, Stefan $u Department of Urology, Goethe-University Frankfurt, Frankfurt am Main, Germany. Electronic address: stefanvallo@gmx.de.
245    10
$a Comparative analysis of the effect of prostatic invasion patterns on cancer-specific mortality after radical cystectomy in pT4a urothelial carcinoma of the bladder / $c S. Vallo, C. Gilfrich, M. Burger, B. Volkmer, K. Boehm, M. Rink, FK. Chun, F. Roghmann, V. Novotny, J. Mani, A. Brisuda, R. Mayr, R. Stredele, J. Noldus, M. Schnabel, M. May, HM. Fritsche, A. Pycha, T. Martini, M. Wirth, J. Roigas, PJ. Bastian, P. Nuhn, R. Dahlem, A. Haferkamp, M. Fisch, A. Aziz,
520    9_
$a PURPOSE: To evaluate the prognostic relevance of different prostatic invasion patterns in pT4a urothelial carcinoma of the bladder (UCB) after radical cystectomy. MATERIALS AND METHODS: Our study comprised a total of 358 men with pT4a UCB. Patients were divided in 2 groups-group A with stromal infiltration of the prostate via the prostatic urethra with additional muscle-invasive UCB (n = 121, 33.8%) and group B with continuous infiltration of the prostate through the entire bladder wall (n = 237, 66.2%). The effect of age, tumor grade, carcinoma in situ, lymphovascular invasion, soft tissue surgical margin, lymph node metastases, administration of adjuvant chemotherapy, and prostatic invasion patterns on cancer-specific mortality (CSM) was evaluated using competing-risk regression analysis. Decision curve analysis was used to evaluate the net benefit of including the variable invasion pattern within our model. RESULTS: The estimated 5-year CSM-rates for group A and B were 50.1% and 66.0%, respectively. In multivariable competing-risk analysis, lymph node metastases (hazard ratio [HR] = 1.73, P<0.001), lymphovascular invasion (HR = 1.62, P = 0.0023), soft tissue surgical margin (HR = 1.49, P = 0.026), absence of adjuvant chemotherapy (HR = 2.11, P<0.001), and tumor infiltration of the prostate by continuous infiltration of the entire bladder wall (HR = 1.37, P = 0.044) were significantly associated with a higher risk for CSM. Decision curve analysis showed a net benefit of our model including the variable invasion pattern. CONCLUSIONS: Continuous infiltration of the prostate through the entire bladder wall showed an adverse effect on CSM. Besides including these patients into clinical trials for an adjuvant therapy, we recommend including prostatic invasion patterns in predictive models in pT4a UCB in men.
650    _2
$a senioři $7 D000368
650    _2
$a cévy $x patologie $7 D001808
650    _2
$a karcinom z přechodných buněk $x mortalita $x patologie $x sekundární $x terapie $7 D002295
650    _2
$a adjuvantní chemoterapie $7 D017024
650    _2
$a cystektomie $7 D015653
650    _2
$a lidé $7 D006801
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lymfatické cévy $x patologie $7 D042601
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a resekční okraje $7 D000072662
650    _2
$a lidé středního věku $7 D008875
650    _2
$a hladké svalstvo $x patologie $7 D009130
650    _2
$a invazivní růst nádoru $7 D009361
650    _2
$a staging nádorů $7 D009367
650    _2
$a prostata $x patologie $7 D011467
650    _2
$a rizikové faktory $7 D012307
650    _2
$a míra přežití $7 D015996
650    _2
$a močový měchýř $x patologie $7 D001743
650    _2
$a nádory močového měchýře $x mortalita $x patologie $x terapie $7 D001749
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Gilfrich, Christian $u Department of Urology, St. Elisabeth Medical Center Straubing, Straubing, Germany.
700    1_
$a Burger, Maximilian $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
700    1_
$a Volkmer, Björn $u Department of Urology, Kassel Medical Center, Kassel, Germany.
700    1_
$a Boehm, Katharina $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Rink, Michael $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Chun, Felix K $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Roghmann, Florian $u Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
700    1_
$a Novotny, Vladimir $u Department of Urology, University Hospital Carl Gustav Carus, Dresden Technical University, Dresden, Germany.
700    1_
$a Mani, Jens $u Department of Urology, Goethe-University Frankfurt, Frankfurt am Main, Germany.
700    1_
$a Brisuda, Antonin $u Department of Urology, 2nd Faculty of Medicine and Motol University Hospital, Prague, Czech Republic.
700    1_
$a Mayr, Roman $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany; Department of Urology, General Hospital of Bolzano, Bolzano, Italy.
700    1_
$a Stredele, Regina $u Department of Urology, Kassel Medical Center, Kassel, Germany.
700    1_
$a Noldus, Joachim $u Department of Urology, Marien Hospital Herne, Ruhr-University Bochum, Herne, Germany.
700    1_
$a Schnabel, Marco $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
700    1_
$a May, Matthias $u Department of Urology, St. Elisabeth Medical Center Straubing, Straubing, Germany.
700    1_
$a Fritsche, Hans-Martin $u Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
700    1_
$a Pycha, Armin $u Department of Urology, General Hospital of Bolzano, Bolzano, Italy.
700    1_
$a Martini, Thomas $u Department of Urology, General Hospital of Bolzano, Bolzano, Italy; Department of Urology, University Hospital Mannheim, Mannheim, Germany.
700    1_
$a Wirth, Manfred, $u Department of Urology, University Hospital Carl Gustav Carus, Dresden Technical University, Dresden, Germany. $d 1949- $7 xx0012316
700    1_
$a Roigas, Jan $u Department of Urology, Vivantes Medical Center Im Friedrichshain and Am Urban, Berlin, Germany.
700    1_
$a Bastian, Patrick J $u Department of Urology, Marien Hospital Düsseldorf, Düsseldorf, Germany.
700    1_
$a Nuhn, Philipp $u Department of Urology, University Hospital Mannheim, Mannheim, Germany.
700    1_
$a Dahlem, Roland $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Haferkamp, Axel $u Department of Urology, Goethe-University Frankfurt, Frankfurt am Main, Germany.
700    1_
$a Fisch, Margit $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
700    1_
$a Aziz, Atiqullah $u Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
773    0_
$w MED00008671 $t Urologic oncology $x 1873-2496 $g Roč. 34, č. 10 (2016), s. 432.e1-8
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27283218 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180404 $b ABA008
991    __
$a 20220720101707 $b ABA008
999    __
$a ok $b bmc $g 1288651 $s 1007978
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 34 $c 10 $d 432.e1-8 $e 20160606 $i 1873-2496 $m Urologic oncology $n Urol Oncol $x MED00008671
LZP    __
$a Pubmed-20180404

Find record

Citation metrics

Archiving options